tenofovir alafenamide
Selected indexed studies
- Tenofovir Alafenamide. (Ann Pharmacother, 2016) [PMID:27465879]
- Tenofovir alafenamide fumarate. (Antivir Ther, 2022) [PMID:35499175]
- Tenofovir alafenamide use in pregnant and lactating women living with HIV. (Expert Opin Drug Metab Toxicol, 2020) [PMID:32125906]
_Worker-drafted node — pending editorial review._
Connections
tenofovir alafenamide is a side effect of
Sources
- Tenofovir Alafenamide. (2016) pubmed
- Tenofovir alafenamide fumarate. (2022) pubmed
- Tenofovir alafenamide use in pregnant and lactating women living with HIV. (2020) pubmed
- Tenofovir alafenamide nephrotoxicity: a case report and literature review. (2021) pubmed
- Tenofovir alafenamide versus entecavir in treating patients with chronic hepatitis B: A meta-analysis. (2025) pubmed
- Tenofovir alafenamide (Vemlidy) for hepatitis B. (2017) pubmed
- Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials. (2024) pubmed
- Tenofovir Alafenamide: A Review in Chronic Hepatitis B. (2017) pubmed
- Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection. (2018) pubmed
- Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? (2018) pubmed